Literature DB >> 8630274

Localisation of [131I]MIBG in nude mice bearing SK-N-SH human neuroblastoma xenografts: effect of specific activity.

G Vaidyanathan1, H S Friedman, S T Keir, M R Zalutsky.   

Abstract

The biodistribution of no-carrier-added (n.c.a.) meta-[131I]iodobenzylguanidine ([131I]MIBG) and that prepared by the standard isotopic exchange method were compared in athymic mice bearing SK-N-SH human neuroblastoma xenografts. No advantage in tumour uptake was observed for the n.c.a. preparation. BALB/c nu/nu mice exhibited lower uptake in highly innervated normal tissues (heart and adrenals) than normal BALB/c mice. In another experiment, the distribution of n.c.a. [131I]MIBG in the absence or presence (3-9 micrograms) of MIBG carrier was determined. At both 4 h and 24 h, the heart uptake was reduced by a factor of 1.5 even at a dose of 3 micrograms MIBG. Tumour uptake was not significantly altered by various amounts of unlabelled MIBG at either time point.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8630274      PMCID: PMC2074506          DOI: 10.1038/bjc.1996.226

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  A human neuroblastoma xenograft model for [131I]-metaiodobenzylguanidine (MIBG) biodistribution and targeted radiotherapy.

Authors:  M Rutgers; A A Gubbels; C A Hoefnagel; P A Voûte; L A Smets
Journal:  Prog Clin Biol Res       Date:  1991

2.  No-carrier-added meta-[123I]iodobenzylguanidine: synthesis and preliminary evaluation.

Authors:  G Vaidyanathan; M R Zalutsky
Journal:  Nucl Med Biol       Date:  1995-01       Impact factor: 2.408

3.  Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts.

Authors:  M N Gaze; T G Hamilton; R J Mairs
Journal:  Br J Radiol       Date:  1994-06       Impact factor: 3.039

4.  Dopamine- -hydroxylase activity in mouse neuroblastoma tumors and in cell cultures.

Authors:  B Anagnoste; L S Freedman; M Goldstein; J Broome; K Fuxe
Journal:  Proc Natl Acad Sci U S A       Date:  1972-07       Impact factor: 11.205

5.  Meta-[211At]astatobenzylguanidine: further evaluation of a potential therapeutic agent.

Authors:  G Vaidyanathan; D K Strickland; M R Zalutsky
Journal:  Int J Cancer       Date:  1994-06-15       Impact factor: 7.396

6.  No-carrier-added synthesis of meta-[131I]iodobenzylguanidine.

Authors:  G Vaidyanathan; M R Zalutsky
Journal:  Appl Radiat Isot       Date:  1993-03       Impact factor: 1.513

7.  No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.

Authors:  R J Mairs; S H Cunningham; J Russell; A Armour; J Owens; K McKellar; M N Gaze
Journal:  J Nucl Med       Date:  1995-06       Impact factor: 10.057

8.  Cytotoxicity of alpha-particle-emitting m-[211At]astatobenzylguanidine on human neuroblastoma cells.

Authors:  D K Strickland; G Vaidyanathan; M R Zalutsky
Journal:  Cancer Res       Date:  1994-10-15       Impact factor: 12.701

9.  Accumulation of m-iodobenzylguanidine by neuroblastoma cells results from independent uptake and storage mechanisms.

Authors:  P G Montaldo; M Lanciotti; A Casalaro; P Cornaglia-Ferraris; M Ponzoni
Journal:  Cancer Res       Date:  1991-08-15       Impact factor: 12.701

10.  Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction.

Authors:  R J Mairs; A Livingstone; M N Gaze; T E Wheldon; A Barrett
Journal:  Br J Cancer       Date:  1994-07       Impact factor: 7.640

View more
  5 in total

1.  Radiation dose estimation using preclinical imaging with 124I-metaiodobenzylguanidine (MIBG) PET.

Authors:  Chang-Lae Lee; Hilla Wahnishe; George A Sayre; Hyo-Min Cho; Hee-Joung Kim; Miguel Hernandez-Pampaloni; Randall A Hawkins; Shorouk F Dannoon; Henry F VanBrocklin; Melissa Itsara; William A Weiss; Xiaodong Yang; Daphne A Haas-Kogan; Katherine K Matthay; Youngho Seo
Journal:  Med Phys       Date:  2010-09       Impact factor: 4.071

Review 2.  Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.

Authors:  Steven G DuBois; Katherine K Matthay
Journal:  Nucl Med Biol       Date:  2008-08       Impact factor: 2.408

3.  A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.

Authors:  Ganesan Vaidyanathan; Philip C Welsh; Katia C Vitorello; Stacey Snyder; Henry S Friedman; Michael R Zalutsky
Journal:  Eur J Nucl Med Mol Imaging       Date:  2004-06-16       Impact factor: 9.236

4.  Preclinical Evaluation of the Acute Radiotoxicity of the α-Emitting Molecular-Targeted Therapeutic Agent 211At-MABG for the Treatment of Malignant Pheochromocytoma in Normal Mice.

Authors:  Hitomi Sudo; Atsushi B Tsuji; Aya Sugyo; Kotaro Nagatsu; Katsuyuki Minegishi; Noriko S Ishioka; Hiroshi Ito; Keiichiro Yoshinaga; Tatsuya Higashi
Journal:  Transl Oncol       Date:  2019-05-09       Impact factor: 4.243

Review 5.  Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs.

Authors:  Cassandra Miller; Julie Rousseau; Caterina F Ramogida; Anna Celler; Arman Rahmim; Carlos F Uribe
Journal:  Theranostics       Date:  2022-01-01       Impact factor: 11.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.